Sartorius unveiled the Eveo Cell Therapy Platform, an integrated system combining raw materials, closed‑system production modules and QC assays aimed at reducing capacity constraints for autologous cell therapies. The modular platform is designed to decentralize and parallelize production, enabling multiple patient batches with fewer operators and lower clean‑room requirements. Industry experts note that bottlenecks in CAR‑T access are driven by manual steps, limited skilled staff and centralized facilities. Analysis from manufacturing specialists recommends automation, AI‑enabled process control and trained personnel as complementary fixes to shorten vein‑to‑vein timelines and reduce cost per dose. If adopted broadly, integrated platforms and in‑process monitoring could accelerate trial enrollment, lower manufacturing failures and expand access. Regulatory alignment and real‑world validation will determine how quickly hospitals and CDMOs integrate these systems.